WO 2004/050691

SEQUENCE LISTING

<110> University of Cape Town

South African Medical Research Council

<120> A method for the production of HIV-1 Gag Virus-Like Particles

<130> PA132610/PCT

<140> PCT/IB03/

<141> 2003-12-04

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 1549

<212> DNA

<213> Human immunodeficiency virus type 1

<400> 60 gaattcatgg gtgcgagagc gtcaatatta agaggggaaa aattagataa atgggaaaag attaggttaa ggccaggggg aaagaaacat tatatgttaa aacacatagt atgggcgagc 120 agggagctgg aaagatttgc acttaaccct ggccttttag aaacatcaga aggatgtaaa 180 240 caaataatga aacagctaca accagctctc cagacaggaa cagaggaact taaatcatta 300 tacaacacag tagcaactct ctattgtgta catgaaaaga tagaagtacg agacaccaag 360 gaagccttag ataagataga ggaagaacaa aacaaatgtc agcaaaaac gcagcaggca aaagcggctg acgggaaagt cagtcaaaat tatcctatag tgcagaatct ccaagggcaa 420 480 atggtacatc aagccatatc acctagaacc ttgaatgcat gggtaaaagt aatagaagaa 540 aaggctttta gcccagaggt aatacccatg tttacagcat tatcagaagg agccacccca caagatttaa acaccatgtt aaatacagtg gggggacacc aagcagccat gcaaatgtta 600 660 aaagatacta ttaatgaaga ggctgcagaa tgggatagat tacatccagt ccatgcgggg 720 cctattgcac caggccagat gagagaacca aggggaagtg acatagcagg. aactactagt accetteagg aacaaatage atggatgaca agtaacceae etattecagt gggagacate 780 tataaaagat ggataattct ggggttaaat aaaatagtga gaatgtatag cccggtcagc 840 attriggaca taagacaagg gccaaaggaa ccctttcgag actatgtaga tcggttcttt 900 960 aaaactttaa gagctgaaca agctacacaa gaagtaaaaa attggatgac agacaccttg

WO 2004/050691 PCT/IB2003/005634

ttagtccaaa	atgcgaaccc	agattgtaag	accattttga	gagcattagg	accaggggct	1020
acattagaag	aaatgatgac	agcatgtcaa	ggggtgggag	gacctggcca	caaagcaaga	1080
gtattggctg	aggcaatgag	tcaaacaaac	agtggaaaca	taatgatgca	gagaagcaat	1140
tttaaaggcc	ctagaagaat	tgttaaatgt	tttaactgtg	gcaaggaagg	gcacatagcc	1200
agaaattgca	gagcccctag	gaaaaaaggc	tgttggaaat	gtggaaaaga	aggacaccaa	1260
atgaaagact	gcactgagag	gcaggctaat	tttttaggga	aaatttggcc	ttcccacaag	1320
gggaggccag	ggaatttcct	tcagaacaga	ccagagccaa	cagececace	agcagagagc	1380
ttcaggttcg	aagagacaac	ccccgctccg	aaacaggagc	cgatagaaag	ggaaccctta	1440
acttccctca	aatcactctt	tggcagcgac	cccttgtctc	aataaaagta	gggggccaga	1500
caagggaggc	tctcttagac	acaggagcag	atgatacagt	attgtcgac		1549

<210> 2 <211> 1479

<212> DNA

<213> Human immunodeficiency virus type 1

<400> 2 atgggtgcga gagcgtcaat attaagaggg gaaaaattag ataaatggga aaagattagg 60 ttaaggccag ggggaaagaa acattatatg ttaaaacaca tagtatgggc gagcagggag 120 180 ctggaaagat ttgcacttaa ccctggcctt ttagaaacat cagaaggatg taaacaaata atgaaacagc tacaaccagc tctccagaca ggaacagagg aacttaaatc attatacaac 240 acagtagcaa ctctctattg tgtacatgaa aagatagaag tacgagacac caaggaagcc 300 360 ttagataaga tagaggaaga acaaaacaaa tgtcagcaaa aaacgcagca ggcaaaagcg 420 gctgacggga aagtcagtca aaattatcct atagtgcaga atctccaagg gcaaatggta catcaagcca tatcacctag aaccttgaat gcatgggtaa aagtaataga agaaaaggct 480 tttagcccag aggtaatacc catgtttaca gcattatcag aaggagccac cccacaagat 540 600 ttaaacacca tgttaaatac agtgggggga caccaagcag ccatgcaaat gttaaaagat actattaatg aagaggctgc agaatgggat agattacatc cagtccatgc ggggcctatt 660 gcaccaggcc agatgagaga accaagggga agtgacatag caggaactac tagtaccctt 720 caggaacaaa tagcatggat gacaagtaac ccacctattc cagtgggaga catctataaa 780 agatggataa ttctggggtt aaataaaata gtgagaatgt atagcccggt cagcattttg 840 gacataagac aagggccaaa ggaacccttt cgagactatg tagatcggtt ctttaaaact 900 ttaagagctg aacaagctac acaagaagta aaaaattgga tgacagacac cttgttagtc 960 caaaatgcga acccagattg taagaccatt ttgagagcat taggaccagg ggctacatta 1020 gaagaaatga tgacagcatg tcaaggggtg ggaggacctg gccacaaagc aagagtattg 1080 gctgaggcaa tgagtcaaac aaacagtgga aacataatga tgcagagaag caattttaaa 1140 ggccctagaa gaattgttaa atgttttaac tgtggcaagg aagggcacat agccagaaat 1200 tgcagagccc ctaggaaaaa aggctgttgg aaatgtggaa aagaaggaca ccaaatgaaa 1260 gactgcactg agaggcaggc taatttttta gggaaaattt ggccttccca caaggggagg 1320 ccagggaatt tccttcagaa cagaccagag ccaacagccc caccagcaga gagcttcagg 1380 ttcgaagaga caacccccgc tccgaaacag gagccgatag aaagggaacc cttaacttcc 1440 ctcaaatcac tctttggcag cgaccccttg tctcaataa 1479

<210> 3

<211> 513

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 3

Glu Phe Met Gly Ala Arg Ala Ser Ile Leu Arg Gly Glu Lys Leu Asp $10 \ \ \, 15$

Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met $20 \ \ 25 \ \ 30$

Leu Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu 35 45

Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Met Lys $50 \hspace{1cm} 55 \hspace{1cm} 60$

Gln Leu Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Lys Ser Leu 65 70 75 80

Tyr Asn Thr $\dot{\text{Val}}$ Ala Thr Leu Tyr Cys $\dot{\text{Val}}$ His Glu Lys Ile Glu $\dot{\text{Val}}$ 85 90 95

Arg Asp Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys $100 ext{ } 110$

Cys Gln Gln Lys Thr Gln Gln Ala Lys Ala Ala Asp Gly Lys Val Ser 115 120 125

Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln 130 140

Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu 145 150 160

Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu 165 170 175

Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly 180 185

His Gln Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala 195 200 205

Ala Glu Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala Pro 210 215 220

Gly Gln Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser 225 230 240 Thr Leu Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro 245 255 Val Gly Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile 260 270 Val Arg Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro 275 280 285 Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg 290 295 300 Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Asp Thr Leu 305 310 320 Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu 325 330 335 Gly Pro Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val 340 345 350 Gly Gly Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln 355 360 365 Thr Asn Ser Gly Asn Ile Met Met Gln Arg Ser Asn Phe Lys Gly Pro 370 380 Arg Arg Ile Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala 385 400 Arg Asn Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys
405
415 Glu Gly His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu 420 425 430 Gly Lys Ile Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln 435 440 Asn Arg Pro Glu Pro Thr Ala Pro Pro Ala Glu Ser Phe Arg Phe Glu 450 455 460 Glu Thr Thr Pro Ala Pro Lys Gln Glu Pro Ile Glu Arg Glu Pro Leu 465 470 475 480 Thr Ser Leu Lys Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln Lys Gly 485 485 Ala Arg Gln Gly Arg Leu Ser Thr Gln Glu Gln Met Ile Gln Tyr Cys 500 510 WO 2004/050691 PCT/IB2003/005634

<210> 4

<211> 492

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 4

Met Gly Ala Arg Ala Ser Ile Leu Arg Gly Glu Lys Leu Asp Lys Trp $1 \hspace{1cm} 15$

Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met Leu Lys 20 25 30

His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu Asn Pro $\frac{35}{40}$

Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Met Lys Gln Leu 50 60

Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Lys Ser Leu Tyr Asn 65 70 80

Thr Val Ala Thr Leu Tyr Cys Val His Glu Lys Ile Glu Val Arg Asp 85 90 95

Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Cys Gln 100 105 110

Gln Lys Thr Gln Gln Ala Lys Ala Ala Asp Gly Lys Val Ser Gln Asn 115 120 125

Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile 130 140

Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu Lys Ala 145 150 160

Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu Gly Ala 165 170 175

Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln 180 185 190

Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala Ala Glu 195 200 205

Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln 210 . 215 220

Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu 225 230 240

Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro Val Gly Page 5 250

255

Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg 260 265 270 Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu 275 285 Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg Ala Glu 290 295 300 Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Asp Thr Leu Leu Val 305 310 315 Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu Gly Pro 325 330 335 Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly 340 345 Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Thr Asn $355 \ \ 360 \ \ \ 365$ Ser Gly Asn Ile Met Met Gln Arg Ser Asn Phe Lys Gly Pro Arg Arg 370 380 The Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His The Ala Arg Asn 385 395 400 Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly 415 His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys 420 425 430 Ile Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln Asn Arg 445 445 Pro Glu Pro Thr Ala Pro Pro Ála Glu Ser Phe Arg Phe Glu Glu Thr 450 455 460 Thr Pro Ala Pro Lys Gln Glu Pro Ile Glu Arg Glu Pro Leu Thr Ser 465 470 475 480 Leu Lys Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln 485 490